Barclays PLC Editas Medicine, Inc. Transaction History

Barclays PLC

  • $377 Billion
  • Q3 2024

A detailed history of Barclays PLC transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Barclays PLC holds 178,507 shares of EDIT stock, worth $435,557. This represents 0.0% of its overall portfolio holdings.

Number of Shares
178,507
Previous 178,507 -0.0%
Holding current value
$435,557
Previous $607,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024
BUY
$3.39 - $5.96 $193,182 - $339,636
56,986 Added 46.89%
178,507 $607,000
Q2 2024

Aug 14, 2024
SELL
$4.67 - $7.28 $108,353 - $168,910
-23,202 Reduced 16.03%
121,521 $567,000
Q1 2024

May 15, 2024
SELL
$7.03 - $11.07 $947,039 - $1.49 Million
-134,714 Reduced 48.21%
144,723 $1.07 Million
Q4 2023

Feb 15, 2024
BUY
$6.25 - $11.11 $27,631 - $49,117
4,421 Added 1.61%
279,437 $2.83 Million
Q3 2023

Nov 07, 2023
SELL
$6.92 - $9.31 $167,948 - $225,953
-24,270 Reduced 8.11%
275,016 $2.15 Million
Q2 2023

Aug 03, 2023
BUY
$6.36 - $11.47 $153,683 - $277,161
24,164 Added 8.78%
299,286 $2.46 Million
Q1 2023

May 04, 2023
SELL
$7.03 - $11.53 $1.16 Million - $1.91 Million
-165,279 Reduced 37.53%
275,122 $1.99 Million
Q4 2022

Feb 13, 2023
BUY
$8.32 - $13.21 $1.17 Million - $1.85 Million
140,174 Added 46.69%
440,401 $3.91 Million
Q3 2022

Nov 03, 2022
BUY
$12.16 - $19.42 $3.38 Million - $5.4 Million
278,208 Added 1263.49%
300,227 $3.68 Million
Q2 2022

Aug 12, 2022
SELL
$9.99 - $21.35 $93,036 - $198,832
-9,313 Reduced 29.72%
22,019 $261,000
Q1 2022

May 16, 2022
SELL
$14.08 - $27.63 $889,320 - $1.75 Million
-63,162 Reduced 66.84%
31,332 $596,000
Q4 2021

Feb 14, 2022
BUY
$26.55 - $40.57 $99,695 - $152,340
3,755 Added 4.14%
94,494 $2.51 Million
Q3 2021

Nov 09, 2021
BUY
$39.27 - $72.94 $1.07 Million - $1.98 Million
27,145 Added 42.68%
90,739 $3.73 Million
Q2 2021

Aug 13, 2021
SELL
$31.29 - $56.64 $1.28 Million - $2.32 Million
-40,923 Reduced 39.15%
63,594 $3.6 Million
Q1 2021

May 13, 2021
BUY
$39.71 - $90.58 $3.2 Million - $7.31 Million
80,652 Added 337.95%
104,517 $4.39 Million
Q4 2020

Feb 11, 2021
SELL
$27.07 - $84.35 $625,127 - $1.95 Million
-23,093 Reduced 49.18%
23,865 $1.67 Million
Q3 2020

Nov 12, 2020
SELL
$28.06 - $37.16 $111,482 - $147,636
-3,973 Reduced 7.8%
46,958 $1.32 Million
Q2 2020

Aug 12, 2020
BUY
$18.5 - $34.34 $107,670 - $199,858
5,820 Added 12.9%
50,931 $1.51 Million
Q1 2020

May 13, 2020
SELL
$14.88 - $32.78 $424,481 - $935,115
-28,527 Reduced 38.74%
45,111 $896,000
Q4 2019

Feb 10, 2020
BUY
$19.49 - $32.63 $355,887 - $595,823
18,260 Added 32.97%
73,638 $2.18 Million
Q3 2019

Nov 14, 2019
BUY
$22.49 - $26.81 $516,797 - $616,066
22,979 Added 70.93%
55,378 $1.26 Million
Q2 2019

Aug 14, 2019
BUY
$20.48 - $27.76 $382,013 - $517,807
18,653 Added 135.7%
32,399 $802,000
Q1 2019

May 15, 2019
SELL
$19.43 - $26.41 $381,177 - $518,111
-19,618 Reduced 58.8%
13,746 $336,000
Q4 2018

Feb 14, 2019
BUY
$18.19 - $31.79 $276,178 - $482,667
15,183 Added 83.51%
33,364 $759,000
Q3 2018

Nov 14, 2018
BUY
$27.65 - $38.39 $110,434 - $153,329
3,994 Added 28.15%
18,181 $579,000
Q2 2018

Aug 14, 2018
SELL
$31.4 - $41.01 $802,332 - $1.05 Million
-25,552 Reduced 64.3%
14,187 $509,000
Q1 2018

May 15, 2018
BUY
$29.84 - $44.08 $699,031 - $1.03 Million
23,426 Added 143.6%
39,739 $1.32 Million
Q4 2017

Feb 14, 2018
BUY
$21.89 - $31.34 $76,833 - $110,003
3,510 Added 27.42%
16,313 $502,000
Q3 2017

Nov 14, 2017
BUY
$15.81 - $24.01 $202,415 - $307,400
12,803
12,803 $307,000

Others Institutions Holding EDIT

# of Institutions
247
Shares Held
57M
Call Options Held
410K
Put Options Held
394K
View Full List

About Editas Medicine, Inc.

EDIT Quotes by TradingView
  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $168M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email